Published in Circulation on November 22, 2004
Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J (2008) 2.29
Cardiac dyssynchrony analysis using circumferential versus longitudinal strain: implications for assessing cardiac resynchronization. Circulation (2005) 2.09
Mechanisms of enhanced beta-adrenergic reserve from cardiac resynchronization therapy. Circulation (2009) 1.63
Recent advances in cardiac resynchronization therapy: echocardiographic modalities, patient selection, optimization, non-responders--all you need to know for more efficient CRT. Int J Cardiovasc Imaging (2009) 1.51
Electromechanical dyssynchrony and resynchronization of the failing heart. Circ Res (2013) 1.01
Different effect of exercise on left ventricular diastolic time and interventricular dyssynchrony in heart failure patients with and without left bundle branch block. Int J Med Sci (2008) 0.80
Cardiac resynchronization therapy in heart failure patients with atrial fibrillation. Europace (2009) 0.78
Dynamic and site-specific impact of ventricular pacing on left ventricular ejection fraction. Heart Rhythm (2010) 0.78
Adverse response to cardiac resynchronisation therapy in patients with septal scar on cardiac MRI preventing a septal right ventricular lead position. J Interv Card Electrophysiol (2011) 0.78
A new quantification method for mechanical dyssynchrony with three-dimensional echocardiography; segmental time and volume loss for prediction of response to cardiac resynchronisation therapy. Int J Cardiovasc Imaging (2012) 0.75
Single beat determination of intraventricular systolic dyssynchrony in patients with atrial fibrillation and systolic dysfunction. Res Cardiovasc Med (2013) 0.75
[Indication for CRT]. Herzschrittmacherther Elektrophysiol (2009) 0.75
[Indication for cardiac resynchronization therapy: Consensus 2005]. Herzschrittmacherther Elektrophysiol (2006) 0.75
Cardiac resynchronization therapy in clinical practice: need for electrical, mechanical, clinical and logistic synchronization. J Interv Card Electrophysiol (2007) 0.75
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med (2004) 18.38
Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science (2006) 10.25
A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet (2005) 9.62
Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med (2008) 7.31
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med (2005) 6.50
Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol (2005) 5.39
Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med (2007) 5.25
TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest (2004) 4.85
Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation (2003) 4.51
Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc (2008) 4.50
Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science (2011) 4.36
Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation (2007) 3.78
Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science (2011) 3.49
Modern pacemaker and implantable cardioverter/defibrillator systems can be magnetic resonance imaging safe: in vitro and in vivo assessment of safety and function at 1.5 T. Circulation (2004) 3.38
Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation (2005) 3.34
Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA (2003) 3.25
Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest (2005) 3.22
End-stage renal disease predicts complications in pacemaker and ICD implants. J Cardiovasc Electrophysiol (2011) 3.21
Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Nat Clin Pract Cardiovasc Med (2008) 3.19
Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science (2011) 3.18
Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation (2006) 3.01
Arrhythmogenic right ventricular dysplasia: a United States experience. Circulation (2005) 2.94
Tackling heart failure in the twenty-first century. Nature (2008) 2.93
Systolic improvement and mechanical resynchronization does not require electrical synchrony in the dilated failing heart with left bundle-branch block. Circulation (2002) 2.88
A prospective evaluation of a protocol for magnetic resonance imaging of patients with implanted cardiac devices. Ann Intern Med (2011) 2.81
Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation (2005) 2.80
Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation (2006) 2.69
Optimal left ventricular endocardial pacing sites for cardiac resynchronization therapy in patients with ischemic cardiomyopathy. J Am Coll Cardiol (2010) 2.66
Cardiac magnetic resonance assessment of dyssynchrony and myocardial scar predicts function class improvement following cardiac resynchronization therapy. JACC Cardiovasc Imaging (2008) 2.64
Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol (2006) 2.61
Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension (2006) 2.59
Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol (2005) 2.53
Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation (2006) 2.52
High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. Circulation (2008) 2.47
Morphologic variants of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy a genetics-magnetic resonance imaging correlation study. J Am Coll Cardiol (2009) 2.44
Feasibility of image-based simulation to estimate ablation target in human ventricular arrhythmia. Heart Rhythm (2013) 2.42
Initial experience in the use of integrated electroanatomic mapping with three-dimensional MR/CT images to guide catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol (2006) 2.40
Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation (2005) 2.38
Clinical utility and safety of a protocol for noncardiac and cardiac magnetic resonance imaging of patients with permanent pacemakers and implantable-cardioverter defibrillators at 1.5 tesla. Circulation (2006) 2.36
PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest (2005) 2.36
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise. J Am Coll Cardiol (2011) 2.31
The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest (2002) 2.26
Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A (2005) 2.25
L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA (2006) 2.24
Retiming the failing heart: principles and current clinical status of cardiac resynchronization. J Am Coll Cardiol (2002) 2.22
Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res (2004) 2.19
Comprehensive desmosome mutation analysis in north americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Cardiovasc Genet (2009) 2.19
Characterization of acute and subacute radiofrequency ablation lesions with nonenhanced magnetic resonance imaging. Heart Rhythm (2006) 2.17
Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models. Circ Res (2009) 2.11
Cardiac dyssynchrony analysis using circumferential versus longitudinal strain: implications for assessing cardiac resynchronization. Circulation (2005) 2.09
Electrophysiological consequences of dyssynchronous heart failure and its restoration by resynchronization therapy. Circulation (2009) 2.09
Direct visualization of coronary sinus ostium and branches with a flexible steerable fiberoptic infrared endoscope. Heart Rhythm (2005) 2.08
Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol (2007) 2.07
Cardiac resynchronization therapy: Part 1--issues before device implantation. J Am Coll Cardiol (2005) 2.06
Impact of arterial load and loading sequence on left ventricular tissue velocities in humans. J Am Coll Cardiol (2007) 2.05
Multiple reaction monitoring to identify site-specific troponin I phosphorylated residues in the failing human heart. Circulation (2012) 2.05
Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens (2007) 2.01
Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature (2013) 2.00
Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. J Am Coll Cardiol (2003) 1.99
Cardiac resynchronization therapy: Part 2--issues during and after device implantation and unresolved questions. J Am Coll Cardiol (2005) 1.98
Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol (2010) 1.97
Gaps in the ablation line as a potential cause of recovery from electrical isolation and their visualization using MRI. Circ Arrhythm Electrophysiol (2011) 1.95
Functional impact of rate irregularity in patients with heart failure and atrial fibrillation receiving cardiac resynchronization therapy. Eur Heart J (2004) 1.95
Dynamic changes in conduction velocity and gap junction properties during development of pacing-induced heart failure. Am J Physiol Heart Circ Physiol (2007) 1.94
Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. Circ Cardiovasc Genet (2015) 1.94
Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload. J Clin Invest (2011) 1.94
Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation (2011) 1.92
Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res (2005) 1.91
KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet (2003) 1.90
Ventricular-arterial coupling, remodeling, and prognosis in chronic heart failure. J Am Coll Cardiol (2013) 1.86
DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathy. Am J Hum Genet (2006) 1.85
Beat-to-beat three-dimensional ECG variability predicts ventricular arrhythmia in ICD recipients. Heart Rhythm (2010) 1.85
Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov (2007) 1.83
Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation (2008) 1.82
Complications of catheter ablation for atrial fibrillation: incidence and predictors. J Cardiovasc Electrophysiol (2008) 1.81
Automated detection and characterization of complex fractionated atrial electrograms in human left atrium during atrial fibrillation. Heart Rhythm (2007) 1.80
Integrated electroanatomic mapping with three-dimensional computed tomographic images for real-time guided ablations. Circulation (2006) 1.79
Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest (2009) 1.79
A biochemical rationale for the discrete behavior of nitroxyl and nitric oxide in the cardiovascular system. Proc Natl Acad Sci U S A (2003) 1.78
Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol (2009) 1.77
Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence from beta-adrenergic signaling. Proc Natl Acad Sci U S A (2003) 1.76
Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol (2008) 1.75
Incidence and predictors of periprocedural cerebrovascular accident in patients undergoing catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol (2009) 1.74
cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res (2004) 1.73
Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase. J Am Coll Cardiol (2012) 1.72